Quantcast
 
New ETF Book by Larry Connors - Click here to read more


 

Redpoint Bio Releases Three Months and Six Months 2009 Financial Results

Thu. August 20, 2009; Posted: 01:21 AM
Stocks RSS
Aug 19, 2009 (Close-Up Media via COMTEX) -- RPBC | Quote | Chart | News | PowerRating -- Redpoint Bio, a company focused on the development of healthier foods and beverages and new approaches to the treatment of diabetes and obesity, announced financial and operational results for the three months and six months ended June 30.

Redpoint said in an August 13 release that it had approximately $10.0 million in cash, cash equivalents and marketable securities at June 30.

For the three months and six months ended June 30, Redpoint recorded revenue of $0.8 million and $1.9 million, respectively. The revenues were primarily from the Company's collaboration with Givaudan. As previously announced, Givaudan terminated its collaboration with the Company effective May 1. For the three months and six months ended June 30, 2008, Redpoint recorded revenue of $1.0 million and $1.9 million, respectively.

Research and development expenses for the second quarter of 2009 were $1.5 million, compared to $2.2 million for the second quarter of 2008. Research and development expenses for the six months ended June 30, were $3.4 million, compared to $4.2 million in the same period of 2008. The decrease in expenses was primarily attributable to the reductions in staff that the Company announced in February and May of 2009.

Redpoint reported a net loss for the second quarter of 2009 of $2.1 million, or $0.03 per share, compared to $2.6 million, or $0.03 per share, for the second quarter of 2008. The net loss for the six months ended June 30, was $4.6 million, or $0.06 per share, compared to $5.1 million, or $0.06 per share, for the six months ended June 30, 2008.

As a result of these studies, the company initiated development activities for RP44. Redpoint intends to develop RP44 through the GRAS (Generally Recognized as Safe) determination/notification process. The GRAS process involves testing to ensure safety in use and usually requires 12-18 months to complete. RP44 is intended to be used in relatively small quantities in concert with nutritive sweeteners. It acts by amplifying the sweetness intensity thereby reducing the amount of nutritive sweetener required, while retaining the desirable temporal characteristics and "clean sweet taste" associated with sugar.

((Comments on this story may be sent to newsdesk@closeupmedia.com))

For full details for RPBC click here.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Related News [RPBC]
  UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
* Attendance is strictly limited and are filled on a first-come, first-served basis.
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.